Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
3(27%)
Results Posted
0%(0 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
2
18%
Ph phase_2
9
82%

Phase Distribution

2

Early Stage

9

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
9(81.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

11

all time

Status Distribution
Active(6)
Completed(1)
Terminated(2)
Other(2)

Detailed Status

Not yet recruiting3
Active, not recruiting2
unknown2
Recruiting1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
3
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (18.2%)
Phase 29 (81.8%)

Trials by Status

active_not_recruiting218%
recruiting19%
not_yet_recruiting327%
completed19%
unknown218%
terminated19%
withdrawn19%

Recent Activity

3 active trials
Showing 5 of 11
recruitingphase_2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
not_yet_recruitingphase_2

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

NCT06224673
active_not_recruitingphase_2

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

NCT04829604
active_not_recruitingphase_2

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

NCT05426486
not_yet_recruitingphase_2

ARX788 in HER2-positive Metastatic Breast Cancer Patients

NCT06663748
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT01042379Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting
NCT06224673Phase 2

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Not Yet Recruiting
NCT04829604Phase 2

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Active Not Recruiting
NCT05426486Phase 2

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Active Not Recruiting
NCT06663748Phase 2

ARX788 in HER2-positive Metastatic Breast Cancer Patients

Not Yet Recruiting
NCT06578286Phase 2

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Not Yet Recruiting
NCT03255070Phase 1

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Completed
NCT05041972Phase 2

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Withdrawn
NCT05018702Phase 2

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

Unknown
NCT05018676Phase 2

ARX788 in Breast Cancer With Low Expression of HER2

Unknown
NCT02512237Phase 1

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11